Increased lymphoma risk with anti-TNF agents and/or thiopurines in IBD

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2020年 / 1822卷 / 1期
关键词：
D O I：
10.1007/s40278-020-83362-0
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 9
相关论文
共 50 条
  • [21] Hepatotoxicity of Anti-TNF Agents
    Maurizio Bonacini
    Marwan Ghabril
    Herbert L. Bonkovsky
    [J]. Digestive Diseases and Sciences, 2014, 59 : 1070 - 1071
  • [22] Hepatotoxicity of Anti-TNF Agents
    Bonacini, Maurizio
    Ghabril, Marwan
    Bonkovsky, Herbert L.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (05) : 1070 - 1071
  • [23] IBD Indication extrapolation for anti-TNF biosimilars
    Casteele, Niels Vande
    Sandborn, William J.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2015, 12 (07) : 373 - 374
  • [24] Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis
    Shah, Eric D.
    Farida, Jeremy P.
    Siegel, Corey A.
    Chong, Kelly
    Melmed, Gil Y.
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 (04) : 570 - 577
  • [25] Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
    Visuri, I.
    Eriksson, C.
    Mardberg, E.
    Grip, O.
    Gustavsson, A.
    Hjortswang, H.
    Karling, P.
    Montgomery, S.
    Myrelid, P.
    Olen, O.
    Ludvigsson, J. F.
    Halfvarson, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S443 - S444
  • [26] Previous Cancer and/or Lymphoma in Patients with Refractory IBD - Pro: Anti-TNF or Immunosuppressive Treatment
    Laharie, David
    [J]. DIGESTIVE DISEASES, 2014, 32 : 116 - 121
  • [27] Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies
    Beigel, Florian
    Steinborn, Anni
    Schnitzler, Fabian
    Tillack, Cornelia
    Breiteneicher, Simone
    John, Jestinah Mahachie
    Van Steen, Kristel
    Laubender, Ruediger P.
    Goeke, Burkhard
    Seiderer, Julia
    Brand, Stephan
    Ochsenkuehn, Thomas
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (07) : 735 - 744
  • [28] GENETIC RISK OF IBD: PREDICTORS OF LOSS OF RESPONSE AND NEED FOR ANTI-TNF THERAPY
    Ramprasad, Chethan
    Estes, Derek
    Damas, Oriana M.
    Quintero, Maria A.
    Martinez, Adriana
    Abreu, Maria T.
    McCauley, Jacob L.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S986 - S986
  • [29] Clinical use of anti-TNF therapy and increased risk of infections
    Ali, Tauseef
    Kaitha, Sindhu
    Mahmood, Sultan
    Ftesi, Abdul
    Stone, Jordan
    Bronze, Michael S.
    [J]. DRUG HEALTHCARE AND PATIENT SAFETY, 2013, 5 : 79 - 99
  • [30] INCREASED RISK OF ANTI-DRUG ANTIBODIES TO A SECOND ANTI-TNF IN PATIENTS WHO DEVELOPED ANTIBODIES TO THE FIRST ANTI-TNF
    Yanai, Henit A.
    Amir, Shira
    Avni-Biron, Irit
    Perets, Tsachi Tsadok
    Shamir, Raanan
    Dotan, Iris
    Assa, Amit
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S671 - S671
12345